Boris Johnson, Prime Minister of the United Kingdom, poses for a photograph with a vaccine bottle, AstraZeneca / Oxford University Covid-19 candidate.
WPA pool | Getty Images News | Getty Images
The British government and domestic health professionals have accelerated the protection of the coronavirus vaccine developed by AstraZeneca and the University of Oxford. Monitor concerns about a potential link to blood clots.
On Wednesday, the UK̵7;s health and vaccine regulator released recommendations on changes to who should get vaccinated. They now suggest that anyone under the age of 30 should get an alternative vaccine amid concerns that in some situations it could lead to a serious blood clot.
Following a review of the safety of the vaccine, AstraZeneca sparked concerns about reports of rare clotting disorders in a small number of vaccine subjects, both the UK and European Medicines Agency (MHRA). And EMA, respectively) emphasizing that the benefits of the pushrod remain. Outweigh the risks
However, amid worries that the vaccine’s reputation could continue to be damaged, experts rushed to defend it – and one Twitter user commented that officials had entered the mode. “Limitation of damage” already.
On Thursday, Britain’s Health Minister stressed that the risk of developing blood clots following the AstraZeneca Covid vaccination was on par with long haul flights. He said the safety measures around vaccines were strong and helped regulators. “Notice this very rare event”
About Chances of Getting a Blood Clot Matt Hancock Told BBC Breakfast: A. “The safety system we have with this vaccine is so sensitive that it can take up to four in a million events – I say this is a risk on par with long-haul flights.”
Meanwhile, UK Prime Minister Boris Johnson, who received the first vaccine, said: “The best thing people should do is look at what the MHRA has to say, our independent regulators – that’s why we have, that’s why they are independent.
“My advice to people is to go outside and have a second jab,” he said Thursday.
Amid growing concerns that Wednesday’s announcement could lead to vaccination hesitancy in the UK, where the vaccination program has progressed well, more than 31.7 million adults had received the first vaccine so far. present The UK has gone through a vaccine priority group, with people under 50 (no underlying health condition) next to vaccination.
British deputy chief medical officer Jonathan Van-Tam tried to ease concerns on Wednesday, saying reports of thrombosis were “extremely rare”, he also noted. that “Changes in vaccine preferences are commonplace and are course corrections.”
“If you take a large cruise across the Atlantic, it doesn’t make sense that you don’t have to do at least one course of revisions during that trip,” he said in a press release, adding that vaccines will be kept under “review. Carefully “
Vaccine hesitation ‘It’s a clear concern’
Andrew Freedman, an infectious disease reader at Cardiff University School of Medicine, is one of the experts, saying the UK’s take action to limit the use of the AstraZeneca vaccine makes sense.
“It seemed a reasonable decision based on the evidence we have so far a possible causal link between the AZ vaccine and the very rare thrombotic side effect that has been observed,” he told CNBC on Wednesday. Thursday However, he noted the hesitancy of vaccination at the moment. “This is a clear concern”
“It is important to emphasize the message that vaccination has saved lives and has saved thousands of lives in the UK,” he added.
Meanwhile, Andrew Pollard, Oxford University professor of pediatric infections and immunology, who developed the drug with AstraZeneca, said in a statement on Wednesday. “Safety is a priority for us throughout the development of vaccines … and we are confident to see that safety checks continue under close scrutiny by regulators and public health authorities when we are committed to safety.” The vaccine is published all over the world.
I’m not sure
Mainland European countries are likely to have a harder time convincing their citizens that the AstraZeneca vaccine is safe, given the many doubts and disputes surrounding the shooting and its supplies to date.
After a second investigation in filming, the European drug agency also ruled Wednesday that the vaccine was safe. But said it was found The “possible link” between prod and thromboembolic cases is very rare. However, the EMA does not assign any age to the recipient.
Emer Cooke, the agency’s executive director, tried to reassure the public, noting that researchers are still trying to figure out what causes the rare blockage. But a small number of serious, including intracranial venous sinus thrombosis (CVST).
This issue clearly illustrates one of the challenges posed by large vaccination campaigns.When millions of people get these vaccines, very rare events may arise unspecified during clinical trials. She said.
EU leaders met on Wednesday night. But the agreement could not be reached on a coordinated strategy regarding the AstraZeneca vaccine.
To date, four European countries have completely stopped using the AstraZeneca vaccine, including Denmark and the Netherlands, while other groups, including Germany, France and Spain, have imposed age restrictions on vaccination.
Most cases of blood clots identified by regulators occurred in women under 60 within two weeks of the shot. However, officials are still looking for specific risk factors that may have contributed to the phenomenon.
Abnormal blood clotting and low platelets are added as a “very rare” side effect to the vaccine product profile, the EMA added.